2.31
-0.11
(-4.55%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.30 - 2.47 |
| 52 week | 1.59 - 5.50 |
| Open | 2.45 |
| Vol / Avg. | 113,954.00/126,660.00 |
| Mkt cap | 70.50M |
| P/E | - |
| Div/yield | - |
| EPS | -0.89 |
| Shares | 30.52M |
| Beta | 1.27 |
| Inst. own | 11% |
Events
Mar 19, 2013
CytRx Corporation at Roth Conference
Mar 4, 2013
CytRx Corporation at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 3849.29% | -17963.87% |
| Operating margin | -5069.96% | -21052.06% |
| EBITD margin | - | -20938.12% |
| Return on average assets | 47.81% | -46.01% |
| Return on average equity | 91.02% | -66.02% |
| Employees | 15 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 650, 11726 San Vicente Blvd
LOS ANGELES, CA 90049
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)
LOS ANGELES, CA 90049
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
Officers and directors
| Max E. Link Ph.D. | Independent Chairman of the Board | |
| Steven A. Kriegsman | President, Chief Executive Officer, Director | |
| Marvin R. Selter | Independent Vice Chairman of the Board | |
| John Y Caloz | Chief Financial Officer | |
| Daniel Levitt M.D., Ph.D. | Executive Vice President, Chief Medical Officer | |
| Douglas Scott Wieland Ph.D. | Senior Vice President - Drug Development | |
| Benjamin S. Levin | Vice President - Legal Affairs, General Counsel, Corporate Secretary | |
| David J. Haen | Vice President - Business Development | |
| Louis J. Ignarro Ph.D. | Independent Director | |
| Joseph Rubinfeld Ph.D. | Independent Director |